Can a single drug stop JAK2 mutations from turning into cancer?
NCT ID NCT07249840
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This pilot study tests whether the drug ropeginterferon is safe and feasible for 12 people with a JAK2 mutation and high-risk features who do not yet have a blood cancer. Participants receive an injection every 4 weeks and are monitored closely. The goal is to see if this approach can prevent progression to myeloproliferative neoplasms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ropeginterferon alfa-2b
- What this could lead to
- If successful, this could point toward a way to reduce the risk of blood cancers in people with JAK2 mutations.
- What could go wrong
- This is a very early, small pilot study focused on safety and feasibility, not effectiveness. The drug may cause side effects and may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JAK2 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mass General Brigham
RECRUITINGBoston, Massachusetts, 02115, United States